ASCO 2023 Bladder Cancer - Results from #20

Viewing 21-29 of 29 articles

ASCO 2023: Phase I/II Randomized Clinical Trial of In-Clinic Acupuncture Prior to BCG in Patients with High-Risk Non-Muscle Invasive Bladder Cancer

ASCO 2023: Survival Outcomes in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles

ASCO 2023: EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with MIBC: Updated Results for Cohort H

ASCO 2023: Age, Sex, and Race-Related Differences in Outcomes of Patients with Muscle-Invasive Bladder Cancer Treated with Radical Cystectomy: The Role of Biology Versus Access to Standard Medical Care

ASCO 2023: KEYNOTE-905/EV-303: A Phase 3 Study to Evaluate the Efficacy and Safety of Perioperative Pembrolizumab or Pembrolizumab + Enfortumab Vedotin for MIBC

ASCO 2023: EV-104: A First-in-Human Trial of Intravesical Enfortumab Vedotin, an Antibody-Drug Conjugate, in Patients with NMIBC: Interim Results of a Phase 1 Study

ASCO 2023: Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-Risk, Non–muscle-Invasive Urothelial Bladder Cancer (NMIBC): BCGMM; ANZUP 1301

ASCO 2023: A Phase III Randomized Trial of Eribulin with or without Gemcitabine vs Standard of Care for Metastatic Urothelial Carcinoma Refractory to or Ineligible for PD/PDL1 Antibody: SWOG S1937

ASCO 2023: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

1
2